Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations of psychosocial factors with cardiovascular health in aging: insights from the Inlife-Aging Project.

GeroScience·2026
Same author

Nucleic acids in pleural fluid for the etiological diagnosis of pleural effusion.

Translational lung cancer research·2025
Same author

Pleural fluid biomarkers for the diagnosis and management of malignant pleural effusions: a clinical review.

Critical reviews in clinical laboratory sciences·2025
Same author

Pleural Fluid Biomarkers of Pediatric Parapneumonic Effusion.

Diagnostics (Basel, Switzerland)·2025
Same author

Genotype/phenotype relationship in Gaucher disease patients. Novel mutation in glucocerebrosidase gene.

Clinical chemistry and laboratory medicine·2020
Same author

The diagnostic value of pleural fluid homocysteine in malignant pleural effusion.

PloS one·2019

Related Experiment Video

Updated: Jul 25, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K

Towards personalized prostate cancer screening.

Xavier Filella1

  • 1Department of Biochemistry and Molecular Genetics (CDB), IDIBAPS, Hospital Clínic, Barcelona, Catalonia, Spain.

Advances in Laboratory Medicine
|June 26, 2023
PubMed
Summary
This summary is machine-generated.

Prostate cancer (PCa) screening using prostate-specific antigen (PSA) is debated due to conflicting data on mortality reduction and overdiagnosis of indolent tumors. Personalized screening may offer a better risk-benefit balance for individual patients.

Keywords:
4KscorePHIprostate cancerprostate-specific antigen (PSA)screening

More Related Videos

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:08

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

106
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

715

Related Experiment Videos

Last Updated: Jul 25, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K
Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:08

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

106
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

715

Area of Science:

  • Urology
  • Oncology
  • Preventive Medicine

Background:

  • The effectiveness of prostate-specific antigen (PSA) screening for prostate cancer (PCa) remains controversial.
  • Published studies often exhibit methodological flaws, leading to conflicting results regarding mortality reduction.
  • PSA screening increases the detection of indolent prostate tumors, raising concerns about overdiagnosis.

Purpose of the Study:

  • To evaluate the ongoing controversy surrounding PSA-based prostate cancer screening.
  • To discuss the challenges in determining optimal screening parameters like age and risk stratification.
  • To explore the potential of personalized screening strategies.

Main Methods:

  • Review of existing literature on PSA screening for prostate cancer.
  • Analysis of contradictory findings regarding screening benefits and harms.
  • Discussion of alternative biomarkers and personalized risk assessment approaches.

Main Results:

  • Evidence is inconsistent on whether PSA screening reduces prostate cancer mortality.
  • Screening programs lead to increased identification of indolent prostate tumors.
  • Current guidelines generally do not recommend population-wide PCa screening, emphasizing shared decision-making.

Conclusions:

  • The decision to screen for prostate cancer requires careful consideration of risks (overdiagnosis, false positives) and benefits (early detection, potential mortality reduction).
  • Personalized screening approaches, considering individual risk factors, are gaining traction and may refine the risk-benefit evaluation.
  • Further research is needed to optimize screening strategies and biomarker utilization for prostate cancer.